AssetMark’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
Other funds holding FDMT
AssetMark's FDMT Position: Q3 2026 in Review
AssetMark opened a new position in 4D Molecular Therapeutics (FDMT) in Q3 2026: 23 shares worth $329. The stake represents ﹤0.01% of the portfolio and ranks #3526 among its holdings.
110 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.
- AssetMark held 23 shares of 4D Molecular Therapeutics worth $329 as of Q3 2026.
- 4D Molecular Therapeutics was a new AssetMark position in Q3 2026.
- 4D Molecular Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3526 holding.
- 110 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.